RxDoctor Payments Data

Lauren Lambeth, NP

Primary Care · Macon, GANPI 1053738054

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 190 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 43 manufacturers reported payments, led by AbbVie at 38.2% of the total.

$4,220in general payments, 2019–2025

Across 190 payments — averaging $22.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$465
  • Galderma Laboratories, L.p.$259
  • Novartis$191
  • GSK$153
  • Otsuka America Pharmaceutical, Inc.$126
  • plus $1K from 37 others

What the payments were for

  • Food & beverage$4,220100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,220 in reported general payments places this provider in the 85th percentile of 235 primary care providers in Georgia.

See all primary care providers in Georgia

Medicare billing

Part B allowed, 2024
$24,613
Medicare patients
148
Services billed
490

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide26$34,500
MounjaroTirzepatide20$20,954
EliquisApixaban11$16,790
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$16,256
Duloxetine Hcl32$976
Levothyroxine Sodium48$620
Atorvastatin Calcium71$617
Omeprazole49$597
Bupropion XlBupropion Hcl16$488
Carvedilol17$470
Rosuvastatin Calcium52$462
Escitalopram Oxalate33$399
Losartan Potassium54$377
Pantoprazole Sodium26$339
Gabapentin31$331

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$465$34,50026 claims
Lilly USA, LLCMounjaro$106$20,95420 claims
PfizerEliquis$80$16,79011 claims
GSKTrelegy Ellipta$153$16,25613 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$14$62048 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 235 primary care providers in Georgia.

Other primary care in Macon

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →